Table 1. Clinical and demographic characteristics of the cohort comparing between patients treated in non-JSGO-accredited institutions and JSGO-accredited institutions.
| Characteristics | Treated in non-JSGO-accredited institutions (n=3,265) | Treated in JSGO-accredited institutions (n=10,920) | p-value | ||
|---|---|---|---|---|---|
| Year of diagnosis | <0.001 | ||||
| 2006 | 878 (26.8) | 2,317 (21.2) | |||
| 2007 | 738 (22.6) | 2,550 (23.4) | |||
| 2008 | 878 (26.8) | 2,750 (25.2) | |||
| 2009 | 777 (23.8) | 3,303 (30.2) | |||
| Age (yr) | <0.001 | ||||
| ≤40 | 624 (19.1) | 2,683 (24.6) | |||
| ≤50 | 696 (21.3) | 2,428 (22.2) | |||
| ≤60 | 781 (23.9) | 2,503 (22.9) | |||
| ≤70 | 589 (18.0) | 1,827 (16.7) | |||
| >70 | 575 (17.6) | 1,479 (13.5) | |||
| Tumor stage | |||||
| T categories | <0.001 | ||||
| T1B | 1,455 (44.6) | 5,238 (48.0) | |||
| T2 | 982 (30.1) | 3,091 (28.3) | |||
| T3 | 586 (17.9) | 1,956 (17.9) | |||
| T4 | 242 (7.4) | 634 (5.8) | |||
| N categories | 0.021 | ||||
| N0 | 2,436 (74.6) | 7,932 (72.6) | |||
| N1 | 829 (25.4) | 2,997 (27.4) | |||
| M categories | 0.057 | ||||
| M0 | 2,952 (90.4) | 9,791 (89.7) | |||
| M1 | 180 (5.5) | 564 (5.2) | |||
| PAN metastasis | 124 (3.8) | 537 (4.9) | - | ||
| Unclear | 9 (0.3) | 28 (0.3) | - | ||
| Histology | 0.001 | ||||
| SCC | 2,377 (72.8) | 7,754 (71.0) | |||
| Adenocarcinoma | 661 (20.2) | 2,170 (19.9) | |||
| Others | 227 (7.0) | 996 (9.1) | |||
| 1st treatment | 0.004 | ||||
| Surgery | 1,628 (49.9) | 5,607 (51.3) | |||
| Radiation | 1,139 (34.9) | 3,916 (35.9) | |||
| Chemo | 481 (14.7) | 1,347 (12.3) | |||
| Others | 17 (0.5) | 50 (0.5) | |||
Values are presented as number of patients (%).
JSGO, Japan Society of Gynecologic Oncology; M, metastasis; N, node; PAN, para-aortic lymph node; SCC, squamous cell carcinoma; T, tumor.